Skip to main content
TipRanks
Go Ultimate75% OFF

Cytokinetics (KK3A) Q3 2026 Earnings Report

4 Followers

DE:KK3A Q3 2026 EPS Results

Actual EPS
-EUR 1.24
Consensus EPS
-EUR 1.30
Beat/Miss
Beat by +EUR 0.06
One Year Ago EPS
-EUR 2.31

DE:KK3A Q3 2026 Revenue Results

Actual Revenue
EUR 43.15M
Expected Revenue
EUR 38.00M
Beat/Miss
Beat by +EUR 5.15M
YoY Revenue Growth
+2356.46%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
DE:KK3A Upcoming Earnings

Cytokinetics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:KK3A Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-17.77%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Management reported rapid MYQORZO revenue, prescriber, patient, market-share and access growth; positive Phase III ACACIA-HCM results; continued regulatory and pipeline progress; and a substantial cash position. The principal challenges were ongoing operating expenses and net losses, a lower cash balance, REMS and monitoring requirements, a gradual European revenue ramp, and clinical development timelines extending into 2027. Highlights significantly outweighed the lowlights.

Company Guidance

Management reaffirmed full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million and stock-based compensation guidance of $130 million to $140 million; MYQORZO is expected to achieve greater than 50% new-to-brand exit share by year-end, launch in the U.K. this quarter and in additional countries in 2027, with Europe expected to be around 15% of revenue when Europe is mature, meaningful revenue probably in the 2028, 2029 time frame, and availability in all key European markets in 2027; the company expects to submit the nHCM sNDA this quarter, submit to the EMA in early 2027, share CEDAR-HCM adolescent-cohort top line results in early 2027, complete AMBER-HFpEF Cohort 1 enrollment this quarter, and continue COMET-HCM enrollment through 2027.

  • Strong MYQORZO Revenue GrowthMYQORZO generated $44.5 million in net revenue in Q3 2026, up 76% from Q2. U.S. net product revenue was $43.1 million, driven by robust demand, while Europe contributed $1.4 million following the German launch.
  • Significant Expansion in Prescriber BaseNearly 1,100 unique U.S. health care providers had prescribed MYQORZO by the end of Q3, up from more than 700 at the end of Q2. On average, prescribers had treated nearly 4 patients, up from 3, while high-volume CMI writers had treated 7 patients versus 5 in Q2.
  • Patient Demand and New-to-Brand Share IncreasedMore than 2,800 patients had been dispensed MYQORZO by the end of Q3, up approximately 86% from 1,500 at the end of Q2. New-to-brand exit share approached 45%, up from approximately 40% in Q2, while share among high-volume CMI prescribers approached 50%. The company remains committed to achieving greater than 50% new-to-brand exit share by year-end.
  • CMI Category ExpansionQ3 2026 versus Q3 2025 new-to-brand prescriptions grew 56%. The CMI market grew 45% on a year-to-date comparison since the introduction of MYQORZO. Management estimated that approximately 120,000 U.S. patients are eligible for oHCM treatment, with only about 28,000 currently treated with a CMI.
  • Broader Adoption Beyond Core PrescribersLow-volume CMI prescribers represented 30% of all MYQORZO prescribers, while prescribers naive to CMI represented another 35%. The CMI-naive prescriber segment accounted for approximately 70% of total CMI growth since Q2. The sales team had reached more than 95% of historically high-volume CMI prescribers.
  • Improved Commercial AccessMore than 60% of commercial lives were covered at the end of Q3, up from 50% at the end of Q2, while Medicare coverage remained at a consistent level throughout 2026. Over 80% of prescriptions were paid prescriptions in Q3.
  • Progress in European LaunchMYQORZO's German launch was described as gaining traction, with more than 50% of new CMI patient starts captured by the end of August. The company received approval in Canada, expects to launch in the U.K. this quarter, and expects MYQORZO to be available in all key European markets in 2027.
  • Positive ACACIA-HCM Phase III ResultsAficamten met both dual primary endpoints in ACACIA-HCM, showing statistically significant improvements versus placebo in patient-reported health status measured by KCCQ and exercise capacity measured by peak VO2. It also achieved significance on 3 of 5 key secondary endpoints, including NYHA class and NT-proBNP.
  • Consistent Aficamten Treatment Effect Across SubgroupsThe ACACIA-HCM treatment effect was consistent across all prespecified subgroups, including patients on beta blockers, patients with intracavitary obstruction, and genotype-positive and genotype-negative patients.
  • Additional Evidence Supporting Aficamten in nHCMAdditional analyses showed that aficamten significantly improved diastolic function and reduced left ventricular wall thickness, with effects strengthening with longer treatment. A separate analysis showed that 53% of aficamten-treated patients achieved a clinically meaningful response in 3 or more exercise domains compared with 13% on placebo.
  • Regulatory Progress for nHCM and oHCMThe supplemental NDA for aficamten in nHCM remains on track for submission to the FDA in Q3 2026, with an EMA application planned for early 2027. The oHCM supplemental NDA based on MAPLE-HCM remained under review with a PDUFA date of November 14.
  • Commercial Preparation for Potential nHCM LaunchThe company is preparing for a potential 2027 nHCM launch using the commercial infrastructure established for oHCM. Management estimated that more than 200,000 patients have been diagnosed with nHCM in the U.S., including more than 120,000 symptomatic and eligible for treatment. Physicians in market research indicated a meaningful role for MYQORZO if approved, particularly for patients with greater symptom burden or persistent functional limitations.
  • Pipeline Clinical Development ProgressASPEN-HCM, a real-world study of MYQORZO in obstructive HCM, began during the quarter. The adolescent cohort of CEDAR-HCM was completed, with top-line results expected in early 2027. Bayer completed the main study treatment period of CAMELLIA-HCM in Japanese patients with obstructive HCM, and the Japan cohort of ACACIA-HCM was completed.
  • Progress in Omecamtiv Mecarbil and Ulacamten ProgramsEnrollment in the Phase III COMET-HCM trial of omecamtiv mecarbil accelerated after all sites became active and is expected to continue through 2027. Enrollment in Cohort 1 of the Phase II AMBER-HFpEF study of ulacamten remained on track for completion this quarter. The company also achieved a preclinical milestone in its collaboration with Accutar on targeted protein degraders for muscle-related diseases.
  • Improved Revenue and Net Loss Compared with Prior YearTotal Q3 revenue was $47.6 million compared with $1.9 million in Q3 2025. Net loss was $190.1 million, or $1.37 per share, compared with a net loss of $306.2 million, or $2.55 per share, in the same period in 2025.
  • Financial Guidance Reaffirmed and Balance Sheet Supports InvestmentThe company reaffirmed full-year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million. Stock-based compensation guidance remained $130 million to $140 million. Cytokinetics ended Q3 with approximately $1.6 billion in cash and investments and said the balance sheet supports launch activities and pipeline advancement.
  • Potential for Long-Term European ContributionManagement expects Europe to represent around 15% of MYQORZO revenue when the U.S. and Europe are mature. The company has submitted dossiers in all major European countries and expects uptake similar to Germany, where physicians are seeing a clear differentiator for MYQORZO.

DE:KK3A Earnings History

DE:KK3A earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)-1.28--1.36――
Nov 04, 20262026 (Q3)-1.30-1.24-2.3146.27% (+1.07)
Aug 06, 20262026 (Q2)-1.48-1.36-1.02-33.93% (-0.34)
May 05, 20262026 (Q1)-1.50-1.52-1.23-22.79% (-0.28)
Feb 24, 20262025 (Q4)-1.42-1.36-1.14-19.05% (-0.22)
Nov 05, 20252025 (Q3)-1.43-2.31-1.23-87.50% (-1.08)
Aug 07, 20252025 (Q2)-1.30-1.02-1.1914.50% (+0.17)
May 06, 20252025 (Q1)-1.24-1.23-1.21-2.26% (-0.03)
Feb 27, 20252024 (Q4)-1.08-1.14-1.258.70% (+0.11)
Nov 06, 20242024 (Q3)-1.12-1.23-1.22-0.74% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed